All articles tagged with #sulthiame
A European phase II trial with 240 adults showed that nightly 200–300 mg sulthiame reduced sleep-apnea severity by about 30–50% versus placebo, improving breathing interruptions and oxygenation with no major safety concerns. The results suggest a direct pharmacological approach to sleep-disordered breathing, though longer and broader studies are needed to confirm durability and safety beyond CPAP-centered care.
A European double-blind trial with 298 participants found the drug sulthiame reduced breathing interruptions by up to 47% and improved overnight oxygen levels in adults with moderate to severe sleep apnea, suggesting a pill-based alternative to CPAP, though longer studies are needed to assess long-term safety and sustained effects.
A European clinical trial found that the drug sulthiame can significantly reduce breathing disruptions in sleep apnea patients, offering a potential alternative to masks like CPAP, with most side effects being mild and temporary.